Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 27, 2023

SELL
$6.7 - $24.21 $13,634 - $49,267
-2,035 Reduced 4.12%
47,345 $1.14 Million
Q4 2022

Feb 02, 2023

BUY
$4.52 - $10.57 $60,780 - $142,134
13,447 Added 37.42%
49,380 $521,000
Q3 2022

Nov 04, 2022

SELL
$3.43 - $5.62 $42,645 - $69,873
-12,433 Reduced 25.71%
35,933 $161,000
Q2 2022

Aug 03, 2022

BUY
$3.65 - $7.3 $89,895 - $179,791
24,629 Added 103.76%
48,366 $193,000
Q1 2022

May 02, 2022

BUY
$3.4 - $7.88 $43,261 - $100,265
12,724 Added 115.54%
23,737 $173,000
Q4 2021

Feb 23, 2022

SELL
$5.59 - $7.39 $134,461 - $177,759
-24,054 Reduced 68.59%
11,013 $61,000
Q3 2021

Oct 28, 2021

SELL
$5.66 - $8.33 $23,262 - $34,236
-4,110 Reduced 10.49%
35,067 $292,000
Q2 2021

Aug 12, 2021

BUY
$6.71 - $11.04 $262,877 - $432,514
39,177 New
39,177 $330,000
Q1 2021

Apr 26, 2021

SELL
$10.12 - $19.45 $74,807 - $143,774
-7,392 Closed
0 $0
Q4 2020

Feb 02, 2021

SELL
$11.79 - $18.94 $99,625 - $160,043
-8,450 Reduced 53.34%
7,392 $125,000
Q3 2020

Oct 14, 2020

BUY
$10.34 - $15.2 $43,665 - $64,189
4,223 Added 36.35%
15,842 $203,000
Q2 2020

Jul 13, 2020

BUY
$7.81 - $17.0 $37,698 - $82,059
4,827 Added 71.07%
11,619 $163,000
Q1 2020

Apr 29, 2020

SELL
$5.42 - $17.75 $173 - $568
-32 Reduced 0.47%
6,792 $62,000
Q4 2019

Feb 05, 2020

SELL
$5.84 - $14.9 $648 - $1,653
-111 Reduced 1.6%
6,824 $101,000
Q3 2019

Oct 15, 2019

BUY
$6.83 - $13.0 $47,366 - $90,155
6,935 New
6,935 $47,000

Others Institutions Holding PRVB

# of Institutions
1
Shares Held
170K
Call Options Held
0
Put Options Held
0

About Provention Bio, Inc.


  • Ticker PRVB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 81,549,904
  • Description
  • Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...
More about PRVB
Track This Portfolio

Track Simplex Trading, LLC Portfolio

Follow Simplex Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.